Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a strategic partnership with Eyenovia, Inc. for the development of novel ophthalmic therapeutic; and Singapore Eye Research Institute to develop ophthalmic formulations for corneal diseases. Formosa Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Taipei City, Taiwan.
Frequently asked questions
What sector does Formosa Pharmaceuticals, Inc. (6838) operate in?
Formosa Pharmaceuticals, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Formosa Pharmaceuticals, Inc. (6838) current stock price?
As of the latest data, Formosa Pharmaceuticals, Inc. stock price is NT$23.00, with a previous close of NT$23.05. Formosa Pharmaceuticals, Inc. lost -NT$0.05 in the last trading session, representing a -0.22% loss.
What is Formosa Pharmaceuticals, Inc. (6838) current market capitalization?
Formosa Pharmaceuticals, Inc. market cap is approximately 3.47 billion.
What is Formosa Pharmaceuticals, Inc. (6838) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.55.
Does Formosa Pharmaceuticals, Inc. (6838) pay dividends?
No. Formosa Pharmaceuticals, Inc. does not pay a dividend.
What is Formosa Pharmaceuticals, Inc. (6838) beta (volatility) score?
Formosa Pharmaceuticals, Inc. has a beta of 0.634, indicating lower volatility than the overall market.
